Almac designs and provides blinding, packaging and logistics services for global clinical trials, incorporating leading technologies and efficient solutions through the most experienced supply chain management in the marketplace.
Commercial drug procurement
Almac provides an end-to-end global commercial drug procurement service and has experience across all major clinical trial markets, product types and assurance of supply.
With vast experience in this area, as well as a reliable network of quality suppliers and wholesalers, Almac has successfully sourced comparator products across all clinical markets, assuring supply for thousands of clinical studies.
Clinical supply chain management
Supply chain management allows Almac to anticipate the needs, challenges and opportunities in the evolving and ever-changing industry of global clinical trials.
Almac can assume full responsibility for end-to-end management of the clinical supply chain.
Clinical packaging (primary)
Almac offers flexible, global and automated clinical packaging solutions of investigational products into a range of formats, including blistering, bottling and carding (walleting).
Clinical packaging (secondary)
Almac’s expertise in secondary packaging of clinical trial supplies includes kit design, label design and production, production of patient kits (automated or semi-automated) and compilation.
Clinical storage and distribution
Almac offers global distribution of clinical materials, an integrated depot network and end-to-end supply chain solution for movement of clinical materials across all key markets to sites.
Almac provides the physical and digital assets to control the distribution of temperature sensitive investigational products. End-to-end solutions provide a managed cold chain that both delivers supplies to the site and provides ownership of the data that drives down excursions and maximises compliance.
Qualified person services
Almac has a full complement of qualified persons (QP) and an experienced support team that assists clients in the release of investigational medical products (IMP) for use in clinical trials, including the importation of these into the EU when necessary.